{"id":"amisulpride-iv-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Parkinsonism"},{"rate":null,"effect":"Hyperprolactinemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amisulpride preferentially antagonizes dopamine receptors in the mesolimbic and mesocortical pathways at low doses, and in the nigrostriatal pathway at higher doses. This dopamine blockade is thought to reduce psychotic symptoms and improve mood regulation. The IV formulation allows for rapid onset of action compared to oral administration.","oneSentence":"Amisulpride is a selective dopamine D2/D3 receptor antagonist that blocks dopamine signaling in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:11.295Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute psychosis or schizophrenia (IV formulation for rapid symptom management)"}]},"trialDetails":[{"nctId":"NCT07348172","phase":"EARLY_PHASE1","title":"Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-03-01","conditions":"Drug Liking","enrollment":100},{"nctId":"NCT05546359","phase":"PHASE2, PHASE3","title":"Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2024-01-18","conditions":"Nausea and Vomiting, Postoperative","enrollment":453},{"nctId":"NCT06585540","phase":"PHASE3","title":"A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population","status":"RECRUITING","sponsor":"Benaroya Research Institute","startDate":"2024-09-13","conditions":"Post Operative Nausea and Vomiting","enrollment":100},{"nctId":"NCT05822713","phase":"PHASE3","title":"A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical (Hainan) Co., Ltd.","startDate":"2023-04-29","conditions":"PONV","enrollment":516},{"nctId":"NCT04954365","phase":"","title":"Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment","status":"WITHDRAWN","sponsor":"Acacia Pharma Ltd","startDate":"2022-11-01","conditions":"Nausea and Vomiting, Postoperative","enrollment":""},{"nctId":"NCT01991860","phase":"PHASE3","title":"US Phase III Study of APD421 in PONV","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-08","conditions":"PONV","enrollment":364},{"nctId":"NCT02646566","phase":"PHASE3","title":"Study of APD421 as PONV Treatment (Prior Prophylaxis)","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2016-03","conditions":"Postoperative Nausea and Vomiting","enrollment":705},{"nctId":"NCT02449291","phase":"PHASE3","title":"Study of APD421 as PONV Treatment (no Prior Prophylaxis)","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2015-09","conditions":"Postoperative Nausea and Vomiting","enrollment":568}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Amisulpride IV Treatment","genericName":"Amisulpride IV Treatment","companyName":"Benaroya Research Institute","companyId":"benaroya-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amisulpride is a selective dopamine D2/D3 receptor antagonist that blocks dopamine signaling in the brain. Used for Acute psychosis or schizophrenia (IV formulation for rapid symptom management).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}